Turing Pharma reduces cost of Daraprim in the USA

26 November 2015

Privately-held drugmaker Turing Pharmaceuticals, via a statement from its Zug, Switzerland, office, unveiled significant price cuts for hospitals on Daraprim (pyrimethamine).

The company, and its USA-based chief executive Martin Shkreli, have come under a great deal of criticism and political approbation, after the company acquired rights to Daraprim from Impax Laboratories (The Pharma Letter August 10) and immediately raised the price from $13.50 per tablet to $750.

"Combined with our robust patient access programs, this is an important step in our commitment to ensure ready access to Daraprim at the lowest possible out-of-pocket cost for both hospitals and patients," said Nancy Retzlaff Turing's chief commercial officer adding: "We pledge that no patient needing Daraprim will ever be denied access."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK